MET and neoplasm: Beyond the outgrowth of mutant BRAF, we identified two additional genetic alterations in the resistant tumor that could contribute to EGFR TKI resistance: focal amplification of 7q31.2 encoding MET in the resistant tumor cells (Fig. 1B and Fig. S1), a low frequency EGFRT790M mutation (14% variant frequency) (Fig. 1B,C).